JP2014511682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511682A5 JP2014511682A5 JP2014501664A JP2014501664A JP2014511682A5 JP 2014511682 A5 JP2014511682 A5 JP 2014511682A5 JP 2014501664 A JP2014501664 A JP 2014501664A JP 2014501664 A JP2014501664 A JP 2014501664A JP 2014511682 A5 JP2014511682 A5 JP 2014511682A5
- Authority
- JP
- Japan
- Prior art keywords
- binding
- seq
- molecule
- sequence
- dll4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 3
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 102000007562 Serum Albumin Human genes 0.000 claims 3
- 108010071390 Serum Albumin Proteins 0.000 claims 3
- 108700041286 delta Proteins 0.000 claims 3
- 101150109170 dll4 gene Proteins 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11160920 | 2011-04-01 | ||
| EP11160920.2 | 2011-04-01 | ||
| PCT/EP2012/055897 WO2012131076A1 (en) | 2011-04-01 | 2012-03-30 | BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014511682A JP2014511682A (ja) | 2014-05-19 |
| JP2014511682A5 true JP2014511682A5 (enExample) | 2016-07-07 |
Family
ID=44314095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501664A Ceased JP2014511682A (ja) | 2011-04-01 | 2012-03-30 | Ｄｌｌ４及びＡｎｇ２と結合する二重特異性結合分子 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130078247A1 (enExample) |
| EP (1) | EP2694545B1 (enExample) |
| JP (1) | JP2014511682A (enExample) |
| KR (1) | KR20140016345A (enExample) |
| CN (2) | CN103596977B (enExample) |
| AP (1) | AP2013007086A0 (enExample) |
| AR (1) | AR085919A1 (enExample) |
| AU (1) | AU2012234218A1 (enExample) |
| BR (1) | BR112013025294A2 (enExample) |
| CA (1) | CA2827809A1 (enExample) |
| CL (1) | CL2013002622A1 (enExample) |
| CO (1) | CO6801638A2 (enExample) |
| EA (1) | EA201301109A1 (enExample) |
| EC (1) | ECSP13012996A (enExample) |
| MA (1) | MA35233B1 (enExample) |
| MX (1) | MX337115B (enExample) |
| PE (1) | PE20141157A1 (enExample) |
| PH (1) | PH12013502031A1 (enExample) |
| SG (1) | SG193557A1 (enExample) |
| TN (1) | TN2013000389A1 (enExample) |
| TW (2) | TWI535735B (enExample) |
| UY (1) | UY33997A (enExample) |
| WO (1) | WO2012131076A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| IN2014DN06904A (enExample) * | 2012-03-30 | 2015-05-15 | Boehringer Ingelheim Int | |
| WO2014049100A1 (en) * | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents |
| KR20150060687A (ko) * | 2012-09-28 | 2015-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF-R 제제를 포함하는 약제학적 조합물 |
| AU2015259465A1 (en) | 2014-05-13 | 2016-11-17 | Bioatla Llc | Conditionally active biological proteins |
| CN107540747B (zh) * | 2017-08-09 | 2020-01-24 | 苏州大学附属儿童医院 | 抗人dll4单克隆抗体6f12 |
| CN110950967B (zh) * | 2019-12-13 | 2022-05-13 | 山东民康生物科技有限公司 | 抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法 |
| JP2024534964A (ja) * | 2021-09-10 | 2024-09-26 | ソーター・バイオファーマ・プライベイト・リミテッド | 抗ａｎｇ２抗体、その調製方法及び使用 |
| CN116444675B (zh) * | 2023-05-11 | 2023-12-22 | 亲和(武汉)生命科技有限责任公司 | 一种Pfu DNA聚合酶纳米抗体及其制备方法和应用 |
| WO2025111816A1 (en) * | 2023-11-28 | 2025-06-05 | Eluminex Biosciences Limited | Multispecific fusion proteins targeting angiogenic, inflammatory, and/or fibrotic factors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| EP1278767A4 (en) | 2000-04-12 | 2003-11-12 | Principia Pharmaceutical Corp | ALBUMIN FUSED PROTEINS |
| RU2420537C2 (ru) | 2001-01-17 | 2011-06-10 | Трабьон Фармасьютикалз Инк. | Слитые белки связывающий домен-иммуноглобулин |
| EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
| AU2002364587A1 (en) | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1558645B1 (en) | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| JP2006520584A (ja) | 2002-11-08 | 2006-09-14 | アブリンクス エン．ヴェー． | 安定化単一ドメイン抗体 |
| CN100343304C (zh) | 2002-12-31 | 2007-10-17 | 尼克塔治疗亚拉巴马公司 | 水解稳定的马来酰亚胺封端的聚合物 |
| DK1639011T3 (da) * | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| EP1687338B1 (en) | 2003-11-07 | 2010-10-20 | Ablynx N.V. | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses thereof |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| RU2007117752A (ru) | 2004-10-13 | 2008-11-20 | Аблинкс Н.В. (Be) | Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера |
| EP2479191A3 (en) * | 2005-05-18 | 2013-03-13 | Ablynx N.V. | Improved nanobodiesTM against tumor necrosis factor-alpha |
| JP5489465B2 (ja) * | 2005-12-16 | 2014-05-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法 |
| UA94464C2 (ru) * | 2006-06-06 | 2011-05-10 | Дженентек, Инк. | Выделенное антитело к dll4 и его применение |
| JP2009539870A (ja) | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 血管発生の調節ための組成物および方法 |
| SG175615A1 (en) * | 2006-06-06 | 2011-11-28 | Genentech Inc | Anti-dll4 antibodies and methods using same |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| US20100113339A1 (en) * | 2006-09-08 | 2010-05-06 | Ablynx N. V. | Serum albumin binding proteins with long half-lives |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| EP2139924B1 (en) * | 2007-03-29 | 2016-07-06 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| CN101965362A (zh) | 2008-03-05 | 2011-02-02 | 埃博灵克斯股份有限公司 | 新型抗原结合二聚体-复合物及其制备方法和应用 |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| CA2735900A1 (en) * | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Antibodies directed to dll4 and uses thereof |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| UY32920A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
| US20110195494A1 (en) * | 2009-10-02 | 2011-08-11 | Boehringer Ingelheim International Gmbh | Dll4-binging molecules |
| TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
-
2012
- 2012-03-29 US US13/433,354 patent/US20130078247A1/en not_active Abandoned
- 2012-03-30 CN CN201280026737.XA patent/CN103596977B/zh not_active Expired - Fee Related
- 2012-03-30 AU AU2012234218A patent/AU2012234218A1/en not_active Abandoned
- 2012-03-30 EP EP12711200.1A patent/EP2694545B1/en not_active Not-in-force
- 2012-03-30 SG SG2013070792A patent/SG193557A1/en unknown
- 2012-03-30 UY UY0001033997A patent/UY33997A/es unknown
- 2012-03-30 KR KR1020137028119A patent/KR20140016345A/ko not_active Withdrawn
- 2012-03-30 TW TW101111544A patent/TWI535735B/zh not_active IP Right Cessation
- 2012-03-30 TW TW101111526A patent/TWI551612B/zh active
- 2012-03-30 CA CA2827809A patent/CA2827809A1/en not_active Abandoned
- 2012-03-30 MX MX2013011032A patent/MX337115B/es active IP Right Grant
- 2012-03-30 AR ARP120101129A patent/AR085919A1/es unknown
- 2012-03-30 PE PE2013002157A patent/PE20141157A1/es not_active Application Discontinuation
- 2012-03-30 BR BR112013025294A patent/BR112013025294A2/pt not_active IP Right Cessation
- 2012-03-30 JP JP2014501664A patent/JP2014511682A/ja not_active Ceased
- 2012-03-30 WO PCT/EP2012/055897 patent/WO2012131076A1/en not_active Ceased
- 2012-03-30 CN CN201610374703.XA patent/CN106046167A/zh active Pending
- 2012-03-30 AP AP2013007086A patent/AP2013007086A0/xx unknown
- 2012-03-30 EA EA201301109A patent/EA201301109A1/ru unknown
-
2013
- 2013-09-12 CL CL2013002622A patent/CL2013002622A1/es unknown
- 2013-09-26 TN TNP2013000389A patent/TN2013000389A1/fr unknown
- 2013-09-27 MA MA36275A patent/MA35233B1/fr unknown
- 2013-09-27 CO CO13230710A patent/CO6801638A2/es unknown
- 2013-09-30 PH PH12013502031A patent/PH12013502031A1/en unknown
- 2013-10-25 EC ECSP13012996 patent/ECSP13012996A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511682A5 (enExample) | ||
| JP2014515602A5 (enExample) | ||
| JP2015143226A5 (enExample) | ||
| CL2014003637A1 (es) | Anticuerpo monoclonal optimizado que se une al gen 3 de activación de linfocitos (lag-3); molécula biespecífica que lo comprende; inmunoconjugado que comprende el anticuerpo unido a un agente terapéutico; composición; ácido nucleico; vector; célula huésped; método de preparación; y uso para inhibir el crecimiento de un tumor o tratar una infección viral. | |
| IL258215B (en) | Antibody anti-mesothelin, nucleic acid encoding said antibody, vector comprising said nucleic acid, host cell comprising said vector, method of preparing said antibody, and pharmaceutical composition for treating cancer or tumor comprising the antibody | |
| JP2010502207A5 (enExample) | ||
| UA115657C2 (uk) | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла | |
| JP2015532292A5 (enExample) | ||
| JP2020536888A5 (enExample) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
| BR112012022102A2 (pt) | polipeptídeos de ligação a a-beta. | |
| WO2011039368A3 (en) | Dll4-binding molecules | |
| JP2016524592A5 (enExample) | ||
| WO2012045882A3 (en) | Phosphospecific antibodies recognising tau | |
| JP2016502515A5 (enExample) | ||
| WO2009048538A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| WO2009048539A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| BR112015012644A2 (pt) | método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit; | |
| WO2013120012A3 (en) | Cdim binding proteins and uses thereof | |
| UA107490C2 (uk) | TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК | |
| JP2016524463A5 (enExample) | ||
| WO2013059559A3 (en) | Compounds and methods for enhancing innate immune responses | |
| EP2753348A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE | |
| JP2011219478A5 (enExample) |